HCW Biologics Inc. announced positive results from studies of its proprietary fusion protein, HCW9206, presented at the 2025 Annual Meeting of American Association of Immunologists. The studies demonstrated that HCW9206 provides a new pathway for generating chimeric T-cell receptor - T cells (CAR-Ts) with increased function.
The activity of HCW9206 was significantly superior to standard methods for CAR lentiviral transduction and subsequent expansion and persistence of human CAR-Ts. It effectively expanded stem cell-like memory T cells (Tscm), which are known for superior in vivo persistence and targeted cell killing.
In humanized mouse models, HCW9206-generated CAR-Ts displayed more potency in suppressing HIV-1 and leukemic cells with enhanced persistence. The GMP master cell bank for HCW9206 has been established, and its drug master file as an ex vivo reagent has been filed with the US FDA, positioning it for commercialization partnerships.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.